Ipilimumab (the CTLA4 inhibitor) and nivolumab/pembrolizumab (the PD-1 inhibitor) have demonstrated great survival benefits for HCC [14, 15]. The gene discussed is CTLA4; the disease is hepatocellular carcinoma.